Evidence map›Paper›PMID 41968383›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2026

Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?

Kowalczyk-Korcz Emilia, Dymińska Magdalena, Groele Lidia, Szypowska Agnieszka

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kowalczyk-Korcz EmiliaDepartment of Pediatric Diabetology and Pediatrics, The Children's Clinical Hospital Named After J.P. Brudziński, University Clinical Center of the Warsaw Medical University, Warsaw, Poland.ORCID https://orcid.org/0000-0002-0231-6784
Dymińska MagdalenaDepartment of Pediatric Diabetology and Pediatrics, The Children's Clinical Hospital Named After J.P. Brudziński, University Clinical Center of the Warsaw Medical University, Warsaw, Poland.ORCID https://orcid.org/0000-0002-6295-2854
Groele LidiaDepartment of Pediatric Diabetology and Pediatrics, The Children's Clinical Hospital Named After J.P. Brudziński, University Clinical Center of the Warsaw Medical University, Warsaw, Poland.ORCID https://orcid.org/0000-0003-4453-4381
Szypowska AgnieszkaDepartment of Pediatric Diabetology and Pediatrics, The Children's Clinical Hospital Named After J.P. Brudziński, University Clinical Center of the Warsaw Medical University, Warsaw, Poland.ORCID https://orcid.org/0000-0002-3407-3174

Funding

DexcomWarszawski Uniwersytet Medyczny
6 · The paper itself

Abstract

aimsTo evaluate whether faster insulin aspart (FIA) improves time in range (TIR) compared with standard insulin aspart (SIA) in children and adolescents with type 1 diabetes achieving glycaemia close to target treated with continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM).

methodsThis prospective, open-label, randomized, 1:1 crossover trial included participants aged 6-17 years with T1D duration of ≥1 year, CSII use ≥3 months, CGM use ≥1 month, and HbA1c 64 mmol/mol (<8%). After a 2-week run-in period, they then crossed over to the alternate insulin for another 4 weeks. All participants used the same CGM system. Assessments were performed at the end of each treatment phase. The primary endpoint was the between-treatment difference in TIR (3.9-10.0 mmol/L, 70-180 mg/dL).

resultsSeventy-seven children were enrolled (mean T1D duration approximately 7 years; 66% male; mean HbA1c 53 mmol/mol, 7%). Mean TIR was 68.5% (SD 12.3%) with SIA and 67.6% (SD 12.1%) with FIA, with no statistically significant difference (mean difference -0.9%; 95% CI -2.60 to 0.86; P = 0.322). Similar patterns were observed for additional glycaemic metrics. Time in tight range was also similar between treatments: 46.3% for SIA versus 45.4% for FIA (P = 0.674).

conclusionsIn this randomised crossover study of children and adolescents with T1D achieving glycaemia close to target on CSII, switching from SIA to FIA does not improve TIR. The absence of improvement across CGM-derived metrics suggests that FIA does not meaningfully enhance glycaemic outcomes in this clinical setting.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulin AspartInsulin Infusion SystemsAdolescentChildContinuous Glucose MonitoringCross-Over StudiesFemaleGlycated HemoglobinHumansMaleProspective StudiesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin Aspartcontinuous blood glucose monitoringGlycaemic controlGlycaemic variabilityinsulin Aspartrapid‐acting insulintreatment outcometype 1 diabetes mellitus

Identifiers

PMID41968383
PMCPMC13380351

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.